Hepatocellular Carcinoma

AASLD Hepatocellular Carcinoma

ASCO GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/76616

Contents of this Issue

Navigation

Page 3 of 7

Figure 1. Algorithm for Investigation of Small Nodules Found on Screening in Patients at Risk for HCC HCC < 1 cm Repeat ultrasound at 3 months Growing/changing character Stable > 1 cm 4-phase MDCT/dynamic contrast enhanced MRI Arterial hypervascularity AND venous or delayed phase washout YES Other contrast enhanced study (CT or MRI) Investigate according to size HCC hypervascularity AND venous or delayed phase washout Arterial YES NO NO Biopsy ÎTo best assess the prognosis of HCC patients it is recommended that the staging system take into account tumor stage, liver function and physical status. The impact of treatment should also be considered when estimating life expectancy. Currently, the Barcelona Clinic Liver Cancer (BCLC) system is the only staging system that accomplishes these aims (II).

Articles in this issue

Archives of this issue

view archives of Hepatocellular Carcinoma - AASLD Hepatocellular Carcinoma